[1] Karkhanis J, Verna E C, Chang M S, et al. Steroid use in acute liver failure[J]. Hepatology, 2014, 59(2): 612-621.
[2] Hartl J, Miquel R, Zachou K, et al. Features and outcome of AIH patients without elevation of IgG[J]. JHEP Rep, 2020, 2(3): 100094.
[3] Tellez L, Sanchez Rodriguez E, Rodriguez de Santiago E, et al. Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study[J]. Aliment Pharmacol Ther, 2022, 56(1): 131-143.
[4] Urzua A, Pizarro C, Gajardo A, et al. Autoimmune hepatitis with acute presentation: clinical, biochemical, and histological features of 126 patients[J]. Can J Gastroenterol Hepatol, 2022, 2022: 6470847.
[5] Mack CL, Adams D, Assis D N, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722.
[6] Lamers M M, van Oijen M G, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials[J]. J Hepatol, 2010, 53(1): 191-198.
[7] Gordon V, Adhikary R, Appleby V, et al. Treatment and outcome of autoimmune hepatitis (AIH): audit of 28 UK centres[J]. Liver Int, 2022.
[8] Li Y N, Ma H, Zhou L, et al. Autoimmune hepatitis-related cirrhosis: clinical features and effectiveness of immunosuppressive treatment in Chinese patients[J]. Chin Med J (Engl), 2016, 129(20): 2434-2440.
[9] Gleeson D, Oo Y, MartynStJames M, et al. P338 First-line treatment of autoimmune hepatitis (AIH): updated systematic review and meta-analysis (SR/MA). In: BMJ Publishing Group, 2024.
[10] Lloyd C, Leighton J, Wong L L, et al. Patient priorities in autoimmune hepatitis: the need for better treatments, more education and challenging stigma[J]. Dig Dis Sci, 2023, 68(1): 87-97.
[11] Diaz-Gonzalez A, Hernandez-Guerra M, Perez-Medrano I, et al. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration[J]. Hepatology, 2023, 77(4): 1095-1105.
[12] Olivas I, Cobreros M, Londono M C, et al. Budesonide in the first line treatment of patients with autoimmune hepatitis[J]. Gastroenterol Hepatol, 2022, 45(7): 561-570.
[13] Harrison L, Hoeroldt B, Dhaliwal H, et al. Long-term outcome of autoimmune hepatitis: consecutive patient cohort and data on the second twenty years[J]. Dig Liver Dis, 2023, 55(11): 1515-1520. |
